


Figure S1.

Efficacy Endpoint: HIV-1 RNA <50 c/mL*

Study 103 – Primary (Wk 48) and Secondary (Wk 96 and 144)



*Virologic success (HIV-1 RNA <50 copies/mL) as defined by FDA Snapshot algorithm

Figure S2.

Difference in Efficacy by Subgroup

Study 103 – Week 144

